Authors' recommendations: Myeloma is a type of cancer that affects white blood cells which are made in the bone marrow. In patients with myeloma, the bone marrow is stopped from making enough normal healthy blood cells. Multiple myeloma can affect many parts of the body and commonly affected areas include the spine, skull, rib cage, pelvis, and the bones of the arms, legs, shoulders, and hips. There is no cure for multiple myeloma; there are drug treatments that help control the disease, but in most patients with multiple myeloma, the disease returns and so the patient needs to be treated again with different drugs. Carfilzomib in combination with dexamethasone is a new drug combination for the treatment of multiple myeloma which is delivered straight into the bloodstream. Studies have suggested carfilzomib in combination with dexamethasone may be helpful for people whose first treatment for multiple myeloma has stopped working. If carfilzomib in combination with dexamethasone is licensed for use in the UK, it could be a new treatment option for patients with multiple myeloma that could improve survival and patients' quality of life.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/carfilzomib-kyprolis-in-combination-with-dexamethasone-for-relapsed-multiple-myeloma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)